Printer Friendly

CELL GENESYS AND MEDIMMUNE TO COLLABORATE ON NOVEL CELL THERAPY FOR AIDS

 CELL GENESYS AND MEDIMMUNE TO COLLABORATE
 ON NOVEL CELL THERAPY FOR AIDS
 FOSTER CITY, Calif., May 5 /PRNewswire/ -- Cell Genesys Inc. announced today that it has signed a collaborative agreement with MedImmune Inc. (NASDAQ: MEDI) through which Cell Genesys will develop novel T cell transplant products for the treatment of human immunodeficiency virus (HIV) infection, the cause of the Acquired Immune Deficiency Syndrome (AIDS). The agreement grants Cell Genesys an exclusive worldwide license to MedImmune's portfolio of anti-HIV antibodies for the development of cytotoxic T cell transplant products for the treatment of AIDS. In exchange, MedImmune will receive licensing fees, payments on milestones achieved, and royalty payments.
 As an initial step toward the development of a T cell transplant product for AIDS, Cell Genesys is genetically modifying human T cells to have increased specificity against HIV. T cells are a type of white blood cell which comprise a major component of the body's immune defense mechanism against certain types of infection and malignancy. The administration of specific T cells to patients with immune deficiency may provide a new therapeutic strategy for the treatment of serious infections such as HIV. For example, a T cell transplant product with specificity against HIV could target cells actively infected with the virus and potentially eliminate sites of persistent infection. However, the therapeutic benefit of an anti-HIV T cell transplant product in AIDS has not yet been demonstrated in human clinical testing, which Cell Genesys does not expect to begin until 1993 or later.
 Cell Genesys' strategy to produce a T cell transplant product targeted against HIV involves the use of human monoclonal antibodies that are broadly reactive against HIV. MedImmune has a large portfolio of human monoclonal antibodies directed against several different components of HIV. By means of genetic engineering technology, Cell Genesys will use components of these antibodies to create T cell transplant products with a high degree of specificity for HIV-infected cells. Moreover, Cell Genesys believes that the genetic modifications to these anti-HIV T cells could allow them to function on a universal basis in the majority of patients who receive them.
 As part of its effort to create anti-HIV T cells, Cell Genesys has an ongoing research collaboration with the New England Deaconess Hospital of Harvard Medical School in Boston and the Medical Biology Institute in San Diego. Together with these two institutions Cell Genesys has received a three year $1.9 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
 "Gaining access to MedImmune's valuable portfolio of anti-HIV antibodies is an important step forward in the development of our anti-HIV T cell transplant product," said Stephen A. Sherwin, M.D., president and chief executive officer of Cell Genesys. "We believe a T cell transplant product may provide a new approach to the therapy of AIDS and may provide insight into the development of similar treatment strategies for other serious infections and malignancies in patients with immunodeficiency."
 "Collaborating with Cell Genesys in the development of anti-HIV T cell therapy for AIDS provides an important opportunity for MedImmune to gain significant incremental value from our expertise and accomplishments in the field of anti-HIV antibodies," said Wayne T. Hockmeyer, Ph.D., MedImmunes's president and chief executive officer.
 Cell Genesys Inc., with headquarters in Foster City, is a privately held biotechnology company, which is a pioneer in the application of gene targeting technology to the development of human therapeutic health care products. The company is using gene targeting and related technologies to develop universal cell transplant products as well as certain human therapeutic protein and human monoclonal antibody products.
 MedImmune Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious disease and cancer. The company's corporate headquarters are located in Gaithersburg, Md.
 -0- 5/5/92
 NOTE: MedImmune Inc. issued a similar news release earlier today, datelined Gaithersburg, Md.
 /CONTACT: Stephen A Sherwin, M.D., of Cell Genesys Inc., 415-358-9600, ext. 212/
 (MEDI) CO: Cell Genesys Inc.; MedImmune Inc. ST: California, Maryland IN: MTC SU: LIC


MM -- SF004 -- 6573 05/05/92 12:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:689
Previous Article:MONRO REPORTS FOURTH QUARTER AND ANNUAL EARNINGS STRONG SHOWING IN THREE MONTHS ENDING FISCAL YEAR 1992
Next Article:SECRETARY OF ENERGY AUTHORIZES RESUMPTION OF K-REACTOR RESTART ACTIVITIES AT THE SAVANNAH RIVER SITE


Related Articles
MEDIMMUNE AND CELL GENESYS TO COLLABORATE ON NOVEL CELL THERAPY FOR AIDS
CELL GENESYS AND CELLPRO COLLABORATE ON ANTI-HIV T CELLS FOR AIDS
CELL GENESYS ISSUED BROAD PATENT FOR UNIVERSAL RECEPTOR CELL TECHNOLOGY
KILLER T CELLS REPORTED AS A POTENTIAL GENE THERAPY FOR VIRAL DISEASES AND CANCER
CELL GENESYS COMPLETES ENROLLMENT IN T CELL GENE THERAPY TRIAL FOR AIDS
CELL GENESYS BEGINS PHASE II TRIAL OF T CELL GENE THERAPY FOR AIDS
CELL GENESYS SCIENTISTS ENGINEER IMPROVED ADENOVIRAL VECTORS FOR IN VIVO GENE THERAPY
CELL GENESYS SECURES WORLDWIDE GENE THERAPY PARTNERSHIP FOR AIDS WITH HOECHST MARION ROUSSEL
CELL GENESYS RECEIVES $20 MILLION EQUITY INVESTMENT FROM HOECHST MARION ROUSSEL
CELL GENESYS SCIENTISTS ENGINEER NOVEL STEM CELLS FOR CANCER GENE THERAPY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters